Posts With Tag Phase III Clinical Trial

AstraZeneca's 6-K filing reveals the RESOLUTE Phase III trial results for Fasenra in COPD. The treatment showed numerical improvements but did not meet primary endpoint significance.

Explore AstraZeneca's 6-K filing detailing Imfinzi's Phase III MATTERHORN trial results, showing significant improvements in event-free survival for gastric cancer patients.

MediWound Ltd. files Form 6-K on Feb 12, 2025, announcing the VALUE Global Phase III trial for EscharEx® aimed at treating Venous Leg Ulcers, marking a significant milestone.